دورية أكاديمية
Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma
| العنوان: | Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma |
|---|---|
| المؤلفون: | Peipert, John Devin, Zhao, Fengmin, Lee, Ju-Whei, Shen, Shu-en, Ip, Edward, O’Connell, Nathaniel, Carlos, Ruth C., Graham, Noah, Smith, Mary Lou, Gareen, Ilana F., Raper, Pamela J., Weiss, Matthias, Kumar, Shaji K., Rajkumar, S. Vincent, Cella, David, Gray, Robert, Wagner, Lynne I. |
| المصدر: | JAMA Network Open ; volume 7, issue 3, page e243854 ; ISSN 2574-3805 |
| بيانات النشر: | American Medical Association (AMA) |
| سنة النشر: | 2024 |
| الوصف: | Importance There is substantial interest in capturing cancer treatment tolerability from the patient’s perspective using patient-reported outcomes (PROs). Objective To examine whether a PRO question, item 5 from the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale (GP5), was associated with early treatment discontinuation (ETD) due to adverse events. Design, Setting, and Participants This prospective survey study was conducted from February to April 2023. Among participants in the ECOG-ACRIN E1A11 trial (a phase 3, parallel design trial conducted between 2013 and 2019), patients with newly diagnosed multiple myeloma were randomized to receive bortezomib (VRd) or carfilzomib (KRd) plus lenalidomide and dexamethasone as induction therapy. The GP5 item was administered at baseline (pretreatment) and at 1 month, 2.8 months, and 5.5 months postbaseline. Eligible participants included patients with newly diagnosed multiple myeloma treated at community oncology practices or academic medical centers in the US. Exposures GP5 response options were “very much,” “quite a bit,” “somewhat,” “a little bit,” and “not at all.” Responses at each assessment while undergoing treatment (1 month, 2.8 months, and 5.5 months) were categorized as high adverse event bother (ie, “very much,” and “quite a bit”) and low adverse event bother (ie, “somewhat,” “a little bit,” or “not at all”). In addition, change from baseline to each assessment while undergoing treatment was calculated and categorized as worsening by 1 response category and 2 or more response categories. Main Outcome and Measure ETD due to adverse events (yes vs no) was analyzed using logistic regression adjusting for treatment group, performance status, gender, race, and disease stage. Results Of the 1087 participants in the original trial, 1058 (mean [SD] age 64 [9] years; 531 receiving VrD [50.2%]; 527 receiving KRd [49.8%]) responded to item GP5 and were included in the secondary analysis. A small proportion (142 patients [13.4%]) ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1001/jamanetworkopen.2024.3854 |
| الإتاحة: | https://doi.org/10.1001/jamanetworkopen.2024.3854Test https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2816820/peipert_2024_oi_240171_1710960179.51062.pdfTest |
| رقم الانضمام: | edsbas.B28F9A2B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1001/jamanetworkopen.2024.3854 |
|---|